Intralesional cidofovir for the treatment of recalcitrant periungual warts

Figures & data

Table 1. Characteristics and treatment outcomes for patients with recalcitrant periungual warts treated with intralesional cidofovir.

Characteristic	Patient Data (n = 9)
Female, n (%)	4 (44.4)
Age, years, n (%)
20–29	3 (33.3)
30–39	2 (22.2)
50–59	1 (11.1)
60–69	1 (11.1)
70–79	1 (11.1)
80–89	1 (11.1)
Number of warts, n (%)
1	5 (55.6)
2–3	3 (33.3)
4–5	1 (11.1)
Wart duration, years, n (%)
2–3	3 (33.3)
4–5	3 (33.3)
>5	3 (33.3)
≥3 prior wart treatments^a, n (%)	9 (100)
OTC treatments^b, n (%)	5 (55.6)
Prior cryotherapy, n (%)	8 (88.9)
History of cancer, n (%)	1 (11.1)
Number of treatments, mean (SD)	2.7 (0.87)
Improved^c, n (%)	9 (100)
90–100% Resolution^c, n (%)	7 (77.8)

OTC, Over the counter.

^aPrior wart treatments include Candida injection, cryotherapy, electrodesiccation/curettage, excision, 5-fluorouracil, imiquimod, and salicylic acid.

^bThese include OTC liquid nitrogen, salicylic acid, and 5-fluorouracil-salicylic acid preparations.

^cImprovement was patient-reported. A resolution was determined by the clinician exam.

Figure 1. A single periungual wart on the finger of a patient (A) before and (B) 6 weeks after one injection of 0.2 mL of intralesional cidofovir (25 mg/mL).

Data availability statement

The data that support the findings of this study are available from the corresponding author, JD, upon reasonable request.